1
|
Bhabha FK, McCormack C, Campbell BA, Lade S, Buelens O, Van Der Weyden C, Prince HM. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre. Australas J Dermatol 2023; 64:194-203. [PMID: 36892928 DOI: 10.1111/ajd.14016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 02/01/2023] [Accepted: 02/12/2023] [Indexed: 03/10/2023]
Abstract
The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
Collapse
Affiliation(s)
- Friyana K Bhabha
- Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Christopher McCormack
- Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Belinda A Campbell
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.,Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia
| | - Stephen Lade
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Odette Buelens
- Nurse Practitioner, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Carrie Van Der Weyden
- Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - H Miles Prince
- Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Schwarting R, Behling E, Allen A, Arguello-Guerra V, Budak-Alpdogan T. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. Arch Pathol Lab Med 2022; 146:415-432. [PMID: 35299246 DOI: 10.5858/arpa.2021-0338-ra] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/14/2021] [Indexed: 11/06/2022]
Abstract
CONTEXT.— In the early 1980s, a monoclonal antibody termed Ki-1 was developed against a cell line derived from a patient with Hodgkin lymphoma. This antibody detected a limited number of benign activated lymphocytes in lymphoid tissue, whereas in Hodgkin lymphoma it appeared to be nearly specific for Reed-Sternberg cells and their mononuclear variants. Subsequent studies showed that Ki-1 expression defined a new type of lymphoma that was later designated anaplastic large cell lymphoma with or without anaplastic large cell kinase expression/translocation. In the past 30 years, numerous new lymphoma entities have been defined, many of which are variably positive for CD30. Many virally transformed lymphoproliferative disorders are also frequently positive for CD30. OBJECTIVE.— To illustrate the broad spectrum of CD30+ hematologic malignancies and to provide an update of CD30-targeted therapies. DATA SOURCES.— Personal experiences and published works in PubMed. CONCLUSIONS.— Because of its low expression in normal tissue, CD30 was studied as a therapeutic target for many years. However, the first functional humanized antibody against CD30 was developed only about 10 years ago. Brentuximab vedotin is a humanized anti-CD30 antibody linked to a cytotoxin, and was approved by the US Food and Drug Administration in 2012 for treating refractory Hodgkin lymphoma and anaplastic large cell lymphoma. Since then, the list of Food and Drug Administration-approved CD30-targeted hematologic malignancies has grown. Recently, the therapies using tumor antigen-specific chimeric antigen receptor T cells targeting CD30 have incited a great deal of enthusiasm and are studied in clinical trials.
Collapse
Affiliation(s)
- Roland Schwarting
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Eric Behling
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Ashleigh Allen
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Vivian Arguello-Guerra
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Tulin Budak-Alpdogan
- MD Anderson Cancer Center at Cooper, Department of Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey (Budak-Alpdogan)
| |
Collapse
|
3
|
Zhang XR, Chien PN, Nam SY, Heo CY. Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment. Cancers (Basel) 2022; 14:1650. [PMID: 35406421 DOI: 10.3390/cancers14071650] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 03/18/2022] [Accepted: 03/21/2022] [Indexed: 11/25/2022] Open
Abstract
Simple Summary Anaplastic large cell lymphoma is a rare type of disease that occurs throughout the world and has four subtypes. A summary and comparison of these subtypes can assist with advancing our knowledge of the mechanism and treatment of ALCL, which is helpful in making progress in this field. Abstract Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin’s lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large cell lymphoma into four categories: ALK-positive ALCL (ALK+ALCL), ALK-negative ALCL (ALK−ALCL), primary cutaneous ALCL (pcALCL), and breast-implant-associated ALCL (BIA-ALCL), respectively. Clinical symptoms, gene changes, prognoses, and therapy differ among the four types. Large lymphoid cells with copious cytoplasm and pleomorphic characteristics with horseshoe-shaped or reniform nuclei, for example, are found in both ALK+ and ALK−ALCL. However, their epidemiology and pathogenetic origins are distinct. BIA-ALCL is currently recognized as a new provisional entity, which is a noninvasive disease with favorable results. In this review, we focus on molecular pathogenesis and management of anaplastic large cell lymphoma.
Collapse
|
4
|
Abstract
Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy options. These options often lack comparative evidence or are characterized by low response rates and short remission duration in relapsed/refractory disease. The approval of mogamulizumab, a humanized, glycoengineered IgG1κ monoclonal antibody targeting the chemokine receptor type 4 (CCR4) chemokine receptor, brings a novel tool into the spectrum of treatment options for advanced CTCL and adult T-cell leukemia/lymphoma (ATLL). CCR4 is expressed in almost all cases of ATLL, and in a majority of CTCLs, particularly when blood involvement is present. In a Phase III randomized trial, mogamulizumab was associated with 28% overall response rate among patients with relapsed CTCL, median progression-free survival of 7.7 months, and median duration of remission of 14.1 months. Responses are more frequent among patients with Sézary syndrome and within the blood compartment. Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogamulizumab may result in severe or refractory graft vs host disease after allogeneic bone marrow transplantation, highlighting the need for vigilance and expert management. Further research may establish incremental efficacy of combining mogamulizumab with cytotoxic or immunomodulatory agents in CTCL, ATLL, and possibly other lymphomas and even solid tumors.
Collapse
Affiliation(s)
- Thomas A Ollila
- Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA, .,Department of Medicine, Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA,
| | - Ilyas Sahin
- Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA, .,Department of Medicine, Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA,
| | - Adam J Olszewski
- Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA, .,Department of Medicine, Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA,
| |
Collapse
|
5
|
Xu H, Liu Q, Li YM, Ma H, Hu HM. Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma. Dermatol Ther 2019; 32:e12834. [PMID: 30659723 DOI: 10.1111/dth.12834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 01/06/2019] [Accepted: 01/15/2019] [Indexed: 11/29/2022]
Abstract
Cutaneous CD30+ lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules, and may spontaneously regress. PC-ALCL presents with solitary tumor or local grouped nodules characterized by large T-cells and may completely or partially resolve in fewer than half of cases. We reported a case of patient with clinical manifestation and pathologic features consistent with LYP in its early stages, which later turned into PC-ALCL. This patient was treated with acitretin combined with NB-UVB and had an obvious response.
Collapse
Affiliation(s)
- Hui Xu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Qi Liu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Yu-Mei Li
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Hong Ma
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Hui-Min Hu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| |
Collapse
|
6
|
Melchers R, Willemze R, Bekkenk M, de Haas E, Horvath B, van Rossum M, Sanders C, Veraart J, Vermeer M, Quint K. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2018; 179:724-731. [DOI: 10.1111/bjd.16501] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/22/2018] [Indexed: 11/27/2022]
Affiliation(s)
- R.C. Melchers
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - R. Willemze
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - M.W. Bekkenk
- Department of Dermatology; Academic Medical Center and Vrije University Medical Center; Amsterdam the Netherlands
| | - E.R.M. de Haas
- Department of Dermatology; Erasmus Medical Center; Rotterdam the Netherlands
| | - B. Horvath
- Department of Dermatology; University Medical Center of Groningen; the Netherlands
| | - M.M. van Rossum
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - C.J.G. Sanders
- Department of Dermatology; University Medical Center Utrecht; the Netherlands
| | - J.C.J.M. Veraart
- Department of Dermatology; Maastricht University Medical Center; the Netherlands
| | - M.H. Vermeer
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - K.D. Quint
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| |
Collapse
|
7
|
Affiliation(s)
- Takashi Onaka
- Kokura Memorial Hospital, Clinic of Hematology, Kitakyushu, Fukuoka, Japan
| | - Tomoya Kitagawa
- Kokura Memorial Hospital, Clinic of Hematology, Kitakyushu, Fukuoka, Japan
| | - Chika Kawakami
- University of Occupational and Environmental, Department of Dermatology, Fukuoka, Japan
| | - Akihito Yonezawa
- Kokura Memorial Hospital, Clinic of Hematology, Kitakyushu, Fukuoka, Japan
| |
Collapse
|
8
|
Stranzenbach R, Dippel E, Schlaak M, Stadler R. Brentuximab vedotin in CD30+cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol 2017; 177:1503-1509. [DOI: 10.1111/bjd.15801] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2017] [Indexed: 12/12/2022]
Affiliation(s)
- R. Stranzenbach
- Department of Dermatology, Venerology, Allergology and Phlebology; Johannes Wesling Medical Centre; University Hospital of Ruhr-University Bochum; Minden Germany
| | - E. Dippel
- Department of Dermatology; Klinikum Ludwigshafen; Skin Cancer Centre Rheinpfalz; Ludwigshafen Germany
| | - M. Schlaak
- Department of Dermatology and Venereology; University of Cologne; Cologne Germany
| | - R. Stadler
- Department of Dermatology, Venerology, Allergology and Phlebology; Johannes Wesling Medical Centre; University Hospital of Ruhr-University Bochum; Minden Germany
| |
Collapse
|
9
|
Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30+primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol 2017; 56:1400-1405. [DOI: 10.1111/ijd.13696] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/25/2017] [Accepted: 06/09/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Tyler H. Enos
- Department of Dermatology; University of Texas Southwestern; Dallas TX USA
| | | | | |
Collapse
|
10
|
Brown RA, Fernandez-Pol S, Kim J. Primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 2017; 44:570-577. [PMID: 28342276 DOI: 10.1111/cup.12937] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 03/15/2017] [Accepted: 03/21/2017] [Indexed: 12/26/2022]
Abstract
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
Collapse
Affiliation(s)
- Ryanne A Brown
- Department of Pathology, Stanford University School of Medicine, Stanford, California
| | | | - Jinah Kim
- Department of Pathology, Stanford University School of Medicine, Stanford, California.,Department of Dermatology, Stanford University School of Medicine, Stanford, California
| |
Collapse
|
11
|
Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol 2016; 176:234-240. [DOI: 10.1111/bjh.14404] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 08/22/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Greg Hapgood
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Tom Pickles
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - Laurie H. Sehn
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Diego Villa
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Richard Klasa
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - David W. Scott
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Alina S. Gerrie
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Randy D. Gascoyne
- Department of Pathology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Graham W. Slack
- Department of Pathology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Christina Parsons
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - James W. Morris
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - Joseph M. Connors
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Kerry J. Savage
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| |
Collapse
|
12
|
Abstract
Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.
Collapse
Affiliation(s)
- Lauren C Hughey
- University of Alabama at Birmingham, 1530 3rd Avenue South, EFH 414, Birmingham, AL 35294, USA.
| |
Collapse
|
13
|
Saintes C, Saint-Jean M, Renaut JJ, Dréno B, Quéreux G. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression. Br J Dermatol 2014; 172:819-21. [PMID: 25113163 DOI: 10.1111/bjd.13337] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C Saintes
- Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France
| | | | | | | | | |
Collapse
|